MiMedx Group (MDXG) said Friday that proxy advisory firm Glass Lewis has recommended that shareholders vote for the re-election of its two director...
...
MiMedx Group (MDXG) has entered a partnership to launch an exclusive version of wound care management firm WoundGenex's Premier Graft Program for its...
MiMedx Group (MDXG) on Monday reported Q4 earnings of $0.01 per diluted share, compared with a loss of $0.17 a year ago. Analysts polled by Capital IQ also...
| Address | 1775 West Oak Commons Court NE Marietta, Georgia 30062 |
| Phone | +1.770.651.9100 |
| Number of Employees | 690 |
| Recent SEC Filing | 05/26/2022 DEFA14A |
| Chief Executive Officer & Director | Timothy R. Wright |
| Senior Vice President-Operations & Procurement | Scott M. Turner |
| Chief Financial Officer | Peter M. Carlson |
| Chief Medical Officer | David H. Mason |
| Price Open | $3.48 |
| Previous Close | $3.47 |
| 52 Week Range | $3.27 - 15.99 |
| Market Capitalization | $408.1 M |
| Shares Outstanding | 113.4 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/02/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$0.17 |
| Beta vs. S&P 500 | N/A |
| Revenue | $245.0 M |
| Net Profit Margin | -4.81% |
| Return on Equity | -14.18% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
